• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肌萎缩侧索硬化症:疾病病理生理学、生物标志物与治疗方法的见解及新前景

Amyotrophic Lateral Sclerosis: Insights and New Prospects in Disease Pathophysiology, Biomarkers and Therapies.

作者信息

Al-Khayri Jameel M, Ravindran Mamtha, Banadka Akshatha, Vandana Chendanda Devaiah, Priya Kushalva, Nagella Praveen, Kukkemane Kowshik

机构信息

Department of Agricultural Biotechnology, College of Agriculture and Food Sciences, King Faisal University, Al-Ahsa 31982, Saudi Arabia.

Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed-to-be-University), Bangalore 560027, India.

出版信息

Pharmaceuticals (Basel). 2024 Oct 18;17(10):1391. doi: 10.3390/ph17101391.

DOI:10.3390/ph17101391
PMID:39459030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11510162/
Abstract

Amyotrophic Lateral Sclerosis (ALS) is a severe neurodegenerative disorder marked by the gradual loss of motor neurons, leading to significant disability and eventual death. Despite ongoing research, there are still limited treatment options, underscoring the need for a deeper understanding of the disease's complex mechanisms and the identification of new therapeutic targets. This review provides a thorough examination of ALS, covering its epidemiology, pathology, and clinical features. It investigates the key molecular mechanisms, such as protein aggregation, neuroinflammation, oxidative stress, and excitotoxicity that contribute to motor neuron degeneration. The role of biomarkers is highlighted for their importance in early diagnosis and disease monitoring. Additionally, the review explores emerging therapeutic approaches, including inhibitors of protein aggregation, neuroinflammation modulators, antioxidant therapies, gene therapy, and stem cell-based treatments. The advantages and challenges of these strategies are discussed, with an emphasis on the potential for precision medicine to tailor treatments to individual patient needs. Overall, this review aims to provide a comprehensive overview of the current state of ALS research and suggest future directions for developing effective therapies.

摘要

肌萎缩侧索硬化症(ALS)是一种严重的神经退行性疾病,其特征是运动神经元逐渐丧失,导致严重残疾并最终死亡。尽管研究不断,但治疗选择仍然有限,这凸显了深入了解该疾病复杂机制并确定新治疗靶点的必要性。本综述对ALS进行了全面审视,涵盖其流行病学、病理学和临床特征。它研究了导致运动神经元变性的关键分子机制,如蛋白质聚集、神经炎症、氧化应激和兴奋性毒性。强调了生物标志物在早期诊断和疾病监测中的重要作用。此外,本综述探讨了新兴的治疗方法,包括蛋白质聚集抑制剂、神经炎症调节剂、抗氧化疗法、基因治疗和基于干细胞的治疗。讨论了这些策略的优势和挑战,重点是精准医学根据个体患者需求定制治疗的潜力。总体而言,本综述旨在全面概述ALS研究的现状,并为开发有效疗法提出未来方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fa6/11510162/27164fe2848d/pharmaceuticals-17-01391-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fa6/11510162/aafab796d0b4/pharmaceuticals-17-01391-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fa6/11510162/27164fe2848d/pharmaceuticals-17-01391-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fa6/11510162/aafab796d0b4/pharmaceuticals-17-01391-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fa6/11510162/27164fe2848d/pharmaceuticals-17-01391-g002.jpg

相似文献

1
Amyotrophic Lateral Sclerosis: Insights and New Prospects in Disease Pathophysiology, Biomarkers and Therapies.肌萎缩侧索硬化症:疾病病理生理学、生物标志物与治疗方法的见解及新前景
Pharmaceuticals (Basel). 2024 Oct 18;17(10):1391. doi: 10.3390/ph17101391.
2
Understanding Amyotrophic Lateral Sclerosis: Pathophysiology, Diagnosis, and Therapeutic Advances.了解肌萎缩侧索硬化症:病理生理学、诊断和治疗进展。
Int J Mol Sci. 2024 Sep 15;25(18):9966. doi: 10.3390/ijms25189966.
3
Recent advances in understanding amyotrophic lateral sclerosis and emerging therapies.肌萎缩侧索硬化症认识的最新进展及新兴疗法
Fac Rev. 2020 Nov 17;9:12. doi: 10.12703/b/9-12. eCollection 2020.
4
Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis.全面研究针对肌萎缩侧索硬化症的治疗策略的过去和未来。
Int J Mol Sci. 2022 Feb 22;23(5):2400. doi: 10.3390/ijms23052400.
5
Current view and perspectives in amyotrophic lateral sclerosis.肌萎缩侧索硬化症的当前观点与展望
Neural Regen Res. 2017 Feb;12(2):181-184. doi: 10.4103/1673-5374.200794.
6
Impact of Plant-Derived Compounds on Amyotrophic Lateral Sclerosis.植物源化合物对肌萎缩性侧索硬化症的影响。
Neurotox Res. 2023 Jun;41(3):288-309. doi: 10.1007/s12640-022-00632-1. Epub 2023 Feb 17.
7
Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS).近年来,在发现治疗肌萎缩侧索硬化症(ALS)的小分子方面取得了进展。
Beilstein J Org Chem. 2013 Apr 15;9:717-32. doi: 10.3762/bjoc.9.82. Print 2013.
8
Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders.靶向肌萎缩侧索硬化症中异常的Nrf2/HO-1信号通路:药物靶点及对神经疾病影响的当前见解
Curr Mol Med. 2021;21(8):630-644. doi: 10.2174/1566524021666210111104920.
9
Therapeutic Approaches to Amyotrophic Lateral Sclerosis from the Lab to the Clinic.肌萎缩侧索硬化症的治疗方法:从实验室到临床。
Curr Drug Metab. 2022;23(3):200-222. doi: 10.2174/1389200223666220310113110.
10
Characteristics of Sensory Neuron Dysfunction in Amyotrophic Lateral Sclerosis (ALS): Potential for ALS Therapy.肌萎缩侧索硬化症(ALS)中感觉神经元功能障碍的特征:ALS治疗的潜力
Biomedicines. 2023 Nov 3;11(11):2967. doi: 10.3390/biomedicines11112967.

引用本文的文献

1
Blueprint of Collapse: Precision Biomarkers, Molecular Cascades, and the Engineered Decline of Fast-Progressing ALS.崩溃蓝图:精准生物标志物、分子级联反应与快速进展性肌萎缩侧索硬化的人为衰退
Int J Mol Sci. 2025 Aug 21;26(16):8072. doi: 10.3390/ijms26168072.
2
Using circular RNAs to target toxic RNA-binding proteins in amyotrophic lateral sclerosis.利用环状RNA靶向肌萎缩侧索硬化症中的毒性RNA结合蛋白。
Mol Ther Methods Clin Dev. 2025 Jun 26;33(3):101525. doi: 10.1016/j.omtm.2025.101525. eCollection 2025 Sep 11.
3
Sephin1 reduces TDP-43 cytoplasmic mislocalization and improves motor neuron survival in ALS models.

本文引用的文献

1
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study.在携带 C9orf72 基因突变的肌萎缩侧索硬化症成人患者中,反义寡核苷酸 BIIB078 的安全性、耐受性和药代动力学:一项 I 期、随机、双盲、安慰剂对照、递增剂量的研究。
Lancet Neurol. 2024 Sep;23(9):901-912. doi: 10.1016/S1474-4422(24)00216-3. Epub 2024 Jul 23.
2
The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets.神经炎症在神经退行性疾病中的作用:当前认识与未来治疗靶点
Front Aging Neurosci. 2024 Apr 12;16:1347987. doi: 10.3389/fnagi.2024.1347987. eCollection 2024.
3
Sephin1可减少肌萎缩侧索硬化症模型中TDP - 43的细胞质错误定位并提高运动神经元存活率。
Life Sci Alliance. 2025 Jul 2;8(9). doi: 10.26508/lsa.202403195. Print 2025 Sep.
4
An Updated and Comprehensive Review Exploring the Gut-Brain Axis in Neurodegenerative Disorders and Neurotraumas: Implications for Therapeutic Strategies.一项探索神经退行性疾病和神经创伤中肠-脑轴的最新综合综述:对治疗策略的启示
Brain Sci. 2025 Jun 18;15(6):654. doi: 10.3390/brainsci15060654.
5
Nanotechnology to Overcome Blood-Brain Barrier Permeability and Damage in Neurodegenerative Diseases.纳米技术克服神经退行性疾病中的血脑屏障通透性及损伤
Pharmaceutics. 2025 Feb 20;17(3):281. doi: 10.3390/pharmaceutics17030281.
6
Resting-State EEG Oscillations in Amyotrophic Lateral Sclerosis (ALS): Toward Mechanistic Insights and Clinical Markers.肌萎缩侧索硬化症(ALS)中的静息态脑电图振荡:寻求机制见解和临床标志物
J Clin Med. 2025 Jan 16;14(2):545. doi: 10.3390/jcm14020545.
Macrophages in immunoregulation and therapeutics.巨噬细胞在免疫调节和治疗中的作用。
Signal Transduct Target Ther. 2023 May 22;8(1):207. doi: 10.1038/s41392-023-01452-1.
4
Biofluid Biomarkers in the Prognosis of Amyotrophic Lateral Sclerosis: Recent Developments and Therapeutic Applications.生物流体生物标志物在肌萎缩侧索硬化症中的预后价值:最新进展与治疗应用。
Cells. 2023 Apr 18;12(8):1180. doi: 10.3390/cells12081180.
5
Blood biomarkers in ALS: challenges, applications and novel frontiers.肌萎缩侧索硬化症中的血液生物标志物:挑战、应用及新前沿。
Acta Neurol Scand. 2022 Oct;146(4):375-388. doi: 10.1111/ane.13698.
6
Trial of Antisense Oligonucleotide Tofersen for ALS.针对肌萎缩侧索硬化症的反义寡核苷酸药物 Tofersen 的试验。
N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705.
7
Superoxide Dismutase 1 Folding Stability as a Target for Molecular Tweezers in SOD1-Related Amyotrophic Lateral Sclerosis.超氧化物歧化酶 1 折叠稳定性作为 SOD1 相关肌萎缩侧索硬化症中分子钳的靶标。
Chembiochem. 2022 Nov 4;23(21):e202200396. doi: 10.1002/cbic.202200396. Epub 2022 Sep 29.
8
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.Tofersen 治疗临床前 SOD1 变异携带者的随机、安慰剂对照、3 期临床试验设计:ATLAS 研究。
Neurotherapeutics. 2022 Jul;19(4):1248-1258. doi: 10.1007/s13311-022-01237-4. Epub 2022 May 18.
9
Microglia Polarization From M1 to M2 in Neurodegenerative Diseases.神经退行性疾病中微胶质细胞从M1型向M2型极化
Front Aging Neurosci. 2022 Feb 16;14:815347. doi: 10.3389/fnagi.2022.815347. eCollection 2022.
10
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis.肌萎缩侧索硬化症中的炎症的基于血液的生物标志物。
Mol Neurodegener. 2022 Jan 24;17(1):11. doi: 10.1186/s13024-022-00515-1.